Delivery Order SPE2DR25D2104-SPE2DR26F3QFC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,952.66 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on November 18, 2025, with completion targeted for November 19, 2025. This is a firm fixed-price, non-competitive set-aside delivery order placed against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $7,796.67 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on November 24, 2025, with completion targeted for November 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Trelegy Ellipta is a combination maintenance inhaler used to treat chronic obstructive pulmonary...
- The Defense Logistics Agency awarded a $1,492.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units). This is a non-competitive delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's corporate headquarters and...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units) with a ceiling value of $1,089.41. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement process. The order is set to reach completion by November 4, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $11,207.26 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on October 31, 2025, with a completion date of November 3, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $48,973.90 for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on November 18, 2025, with completion scheduled for November 19, 2025. This competitive award, issued without set-aside designation, was structured as a firm fixed price delivery order to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,758.08 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count supply) on November 5, 2025, with completion scheduled for November 6, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency awarded a delivery order valued at $39,150.40 to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count). This competitively awarded, firm fixed-price contract is set to be completed by November 19, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $7,668.28 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count) with a completion date of November 17, 2025. This contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary operations for federal...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3QFCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,101.16 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on December 1, 2025, with a completion deadline of December 2, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and represents a continuation of the company's pharmaceutical supply services to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Trelegy Ellipta is a combination respiratory medication used in the treatment of chronic obstructive pulmonary disease, reflecting the contractor's critical role in providing essential brand-name pharmaceuticals to the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 11/30/25 |